Drug repurposing of pyrazolotriazine derivatives as potential anti-SARS-CoV-2 agents: in vitro and in silico studies.

Khulood H Oudah, Mazin A A Najm, Reham F Barghash, Omnia Kutkat, Mohamed GabAllah, Amgad Albohy, Khaled A M Abouzid

Abstract read

In one paragraph

Article in BMC chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Khulood H OudahDepartment of Pharmacy, Mazaya University Collage, Nasiriyah, Thi-Qar, Iraq.ORCID http://orcid.org/0000-0002-5014-7129

Mazin A A NajmDepartment of Pharmacy, Mazaya University Collage, Nasiriyah, Thi-Qar, Iraq.ORCID http://orcid.org/0000-0002-4801-3578

Reham F BarghashInstitute of Chemical Industries Research, National Research Centre, Dokki, Giza, 12622, Egypt.ORCID http://orcid.org/0000-0003-2731-9970

Omnia KutkatCenter of Scientifc Excellence for Infuenza Viruses, National Research Centre, Dokki, Giza, 12622, Egypt.

Mohamed GabAllahCenter of Scientifc Excellence for Infuenza Viruses, National Research Centre, Dokki, Giza, 12622, Egypt.

Amgad AlbohyDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, The British University in Egypt, El-Sherouk City, 11837, Cairo, Egypt. albohy@ualberta.ca.

Khaled A M AbouzidPharmaceutical Chemistry Department, Faculty of Pharmacy, Ain Shams University, Abbassia, 11566, Cairo, Egypt. khaled.abouzid@pharma.asu.edu.eg.

Funding

British University in Egypt YIRG2021-13

6 · The paper itself

Abstract

The search for new molecules targeting SARS-CoV-2 has been a priority since 2020. The continuous evolution of new mutants increases the need for more research in the area. One way to find new leads is to repurpose existing drugs and molecules against the required target. Here, we present the in vitro and in silico screening of ten previously synthesized and reported compounds as anti-COVID 19 agents. The compounds were screened in vitro against VERO-E6 cells to find their Cytotoxic Concentration (CC

Indexed as

COVID 19Drug repurposingMain protease MproMolecular dockingPyrazolotriazineSARS-CoV-2

Identifiers

PMID39014447

DOI10.1186/s13065-024-01233-z

PMCPMC11253567

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.